[regional blood flow in the]{.smallcaps} lung is known to be influenced by experimental manipulations of the alveolar P[o]{.smallcaps}~2~ (P[a]{.smallcaps}~O~2~~) and alveolar P[co]{.smallcaps}~2~ (P[a]{.smallcaps}~CO~2~~) ([@B4]). However, it remains uncertain whether these responses play any significant role in correcting for mismatches of perfusion to ventilation arising during normal daily activities that change ventilation and/or posture as well as during pathological processes such as acute lung injury ([@B24]). In this study, our general aim was to develop the theory necessary to link global measurements of vascular reactivity to P[a]{.smallcaps}~CO~2~~ and P[a]{.smallcaps}~O~2~~ in humans with some measure of their expected influence on ventilation-perfusion matching within the healthy lung.

The particular measure that we have adopted is the efficiency (*E*) of feedback regulation. This measure is given by $$E = 100\left( {1 - h_{1}/h_{0}} \right)$$ where *h*~*0*~ is a step-function disturbance to the system in P[a]{.smallcaps}~CO~2~~ or P[a]{.smallcaps}~O~2~~. In *[Eq. 1](#FD1){ref-type="disp-formula"}*, *h*~*1*~ represents the residual disturbance in P[a]{.smallcaps}~CO~2~~ or P[a]{.smallcaps}~O~2~~ after feedback correction. For example, in an open-loop system (where there is no feedback correction), *h*~*1*~ will equal *h*~*0*~, and so the efficiency will be 0%. On the other hand, for a closed-loop (feedback) system in which the loop gain tends toward infinity so that the error is almost completely corrected, *h*~*1*~ will tend toward zero, and so the efficiency will be close to 100%. The theoretical section of this paper moves from measures of vascular reactivity to P[a]{.smallcaps}~CO~2~~ and P[a]{.smallcaps}~O~2~~ in humans, to estimates of closed-loop gains from which efficiencies of regulation may be calculated.

The particular measure of pulmonary vascular reactivity to variations in P[a]{.smallcaps}~CO~2~~ and P[a]{.smallcaps}~O~2~~ that we adopted for this study is the maximum pressure gradient across the tricuspid valve during systole as assessed by Doppler ultrasound. This variable is denoted by the abbreviation ΔPmax to emphasize that it is a maximum pressure difference between two cardiac chambers. The usefulness of this measure as an index of pulmonary arterial pressure in normal humans has been well documented ([@B1], [@B42]); nevertheless, a difficulty remains, as global variations in P[a]{.smallcaps}~CO~2~~ and P[a]{.smallcaps}~O~2~~ influence not only vascular tone but also cardiac output (Q̇), which independently will influence both vascular tone and pulmonary arterial pressure. The theoretical approach that we have adopted accounts fully for this complication. In the case of O~2~, the required data are already available in the literature. In the case of CO~2~, additional data are required to assess the speed and magnitude of responses over the relevant timescales, and these results form an experimental component of the present study.

In the healthy lung, a regional disturbance of ventilation-to-perfusion ratio would be expected to alter regional P[a]{.smallcaps}~CO~2~~ and P[a]{.smallcaps}~O~2~~, and the efficiency of regulation in this part of the lung will vary with the absolute value of this ratio. The results from this study demonstrate how the efficiency of regulation varies with ventilation-perfusion ratio. It is important to note that the efficiency of feedback regulation *E* defined by *[Eq. 1](#FD1){ref-type="disp-formula"}* is distinct from the more general concept of the efficiency of gas exchange for the lung as a whole. For a lung to be efficient in gas exchange, there may be several requirements. One of these is uniformity of matching of ventilation and perfusion throughout the lung. Another is avoidance of diffusion limitation of gas transfer. In this paper, we restrict ourselves to a computation of *E*. Thus "good" feedback with a high efficiency is seen as feedback that restores the regional values of P[a]{.smallcaps}~CO~2~~ and P[a]{.smallcaps}~O~2~~ toward their normal values from which they have been disturbed and not necessarily toward a single uniform value for the lung as a whole.

Finally, it is important to note that this study is concerned with the contribution to ventilation-perfusion matching from vascular responses to CO~2~ and O~2~. However, previous studies have shown the potential for upper airway detection of CO~2~ and O~2~ to contribute to regional matching of ventilation to perfusion in the lung ([@B6], [@B41]). Thus the efficiencies arising from the pulmonary vascular responses to CO~2~ and O~2~ reported in this study should be viewed as lower bounds to the overall contributions of these gases to ventilation-perfusion matching within the healthy human lung.

METHODS
=======

Overview
--------

This study has two main components. The first component is the development of the theory necessary to predict the efficiency of regulation of regional P[a]{.smallcaps}~CO~2~~ and P[a]{.smallcaps}~O~2~~ from the pulmonary vascular responses to global variations in P[a]{.smallcaps}~CO~2~~ and P[a]{.smallcaps}~O~2~~. The analysis requires experimentally determined coefficients for these responses. These are available from the literature for O~2~, but only in part for CO~2~. The second main component of this study is experimental and provides the measurements of global pulmonary vascular response to hypercapnia and hypocapnia that are required to complete the analysis.

Theory for CO~2~
----------------

In this section, our first purpose is to estimate the steady-state, closed-loop gain (in the normal lung, under normal conditions) for the feedback loop between regional P[a]{.smallcaps}~CO~2~~ and regional pulmonary vascular tone ([Fig. 1](#F1){ref-type="fig"}). This estimate enables an assessment to be made of whether the mechanism contributes significantly to the maintenance of ventilation-perfusion matching within the lung during everyday activities.

![Depiction of the control system regulating the local alveolar P[co]{.smallcaps}~2~ (P[a]{.smallcaps}~CO~2~~) within the lung \[for alveolar P[o]{.smallcaps}~2~ (P[a]{.smallcaps}~O~2~~), the analysis is analogous\]. *A* and *B* illustrate the derivation of *[Eq. 15](#FD5){ref-type="disp-formula"}*. In *A*, the lines represent variables \[e.g., Δ(v̇/q̇), where v̇/q̇ is ventilation-to-perfusion ratio\] within the control system, the rectangular boxes depict the transforms for the change in 1 variable brought about by the change in another, and the circle represents the addition of the changes in 2 incoming variables to generate an outgoing variable. In the absence of any disturbance (i.e., *h*~*0*~ = 0), ΔP[a]{.smallcaps}~CO~2~~ and Δ(v̇/q̇) are both 0, and the control system is at *point 1* (see *B*). A step-function finite disturbance in P[a]{.smallcaps}~CO~2~~ (i.e., *h*~*0*~ ≠ 0) is illustrated at *point 2* in *B*. If no feedback is present (an open loop), then this disturbance would result in a disturbance of v̇/q̇ illustrated at *point 3* in *B*. However, in the presence of feedback (a closed loop), the control system is at *point 4* in *B*. Here, the final value for ΔP[a]{.smallcaps}~CO~2~~ is *h*~*1*~ \[and the final value for Δ(v̇/q̇) is *h*~*1*~H\]. Summation at the junction depicted by the circle in *A* yields the result that ΔP[a]{.smallcaps}~CO~2~~ (= *h*~*1*~) = *h*~*0*~ − KH*h*~*1*~, which is *[Eq. 15](#FD5){ref-type="disp-formula"}*.](zdg0051090370001){#F1}

The approach taken is to consider the feedback loop as a dynamic system composed of two components ([Fig. 1*A*](#F1){ref-type="fig"}). The first component of the loop is a description of the influence of the pulmonary vascular response to CO~2~ on the regional ventilation-to-perfusion ratio (v̇/q̇). The dynamic properties of this component remain to be well characterized, and so the time course of changes in v̇/q̇ in response to changes in regional P[co]{.smallcaps}~2~ is not modeled here. The sensitivity (H) of this component is derived from the experimental measurements of this study together with certain other values taken from the literature. The second component of the loop is a description of the influence of changes in v̇/q̇ on regional P[a]{.smallcaps}~CO~2~~ and follows directly from considerations of mass balance. As for the first component, the dynamic properties of this second component are not well defined and therefore not analyzed in this study. The sensitivity of this part of the feedback loop is termed −K. The product of the two sensitivities yields the closed-loop gain: −K × H.

In [Fig. 1*B*](#F1){ref-type="fig"}, *point 1* represents the regional values of P[a]{.smallcaps}~CO~2~~ and v̇/q̇ before any disturbance has occurred. *Point 2* represents a step-function disturbance *h*~*0*~ in P[a]{.smallcaps}~CO~2~~. If no feedback is present (open loop), then this disturbance would result in a disturbance of v̇/q̇ illustrated at *point 3* in [Fig. 1*B*](#F1){ref-type="fig"}. *Point 4* represents the situation for the closed loop, in which the control system has reduced ΔP[a]{.smallcaps}~CO~2~~ to *h*~*1*~ by inducing a rise in v̇/q̇ equal to Δ(v̇/q̇).

### Estimation of H for CO~2~: effect of changes in regional P[a]{.smallcaps}~CO~2~~ on v̇/q̇.

H is defined as the change in v̇/q̇ that results from a change in the regional P[a]{.smallcaps}~CO~2~~ when the lung continues to be perfused at constant in-flow pressure, in our case specified by the tricuspid valve maximum pressure difference (ΔPmax), which is described in *Experimental Study* below: $$\text{H=}\left( \frac{\partial(\overset{˙}{v}/\overset{˙}{q}\text{)}}{\partial\text{P}_{\text{A}_{\text{CO}_{2}}}} \right)_{\Delta\text{Pmax}}$$

We now assume that a regional change in P[a]{.smallcaps}~CO~2~~ influences regional blood flow but not v̇. There is some evidence, outlined in [discussion]{.smallcaps}, that alveolar gas composition can modify the distribution of v̇ in such a manner as to make our estimate of loop gain a lower bound. *[Equation 2](#FD2){ref-type="disp-formula"}* can be expanded using the quotient rule to obtain one term equal to (1/q̇)(∂v̇/∂P[co]{.smallcaps}~2~)~ΔPmax~ and a second term equal to −(v̇/q̇^2^)(∂q̇/∂P[co]{.smallcaps}~2~)~ΔPmax~ According to our assumption that a regional change in P[a]{.smallcaps}~CO~2~~ does not affect v̇, (∂v̇/∂P[co]{.smallcaps}~2~)~ΔPmax~ becomes equal to zero, the second term can be expressed using a logarithm, and the above expression can be written as follows: $$\left( \frac{\partial(\overset{˙}{v}/\overset{˙}{q}\text{)}}{\partial\text{P}_{\text{A}_{\text{CO}_{2}}}} \right)_{\Delta\text{Pmax}}\left( \frac{\overset{˙}{v}}{\overset{˙}{q}} \right)\left( \frac{\partial\ln\overset{˙}{q}}{\partial\text{P}_{\text{A}_{\text{CO}_{2}}}} \right)_{\Delta\text{Pmax}}$$

The challenge now is to relate a proportional change in regional blood flow (q̇) under the condition of constant perfusion pressure to the measured global changes in flow (Q̇) in the experiments presented in *Experimental Study* below (where perfusion pressure does not in general remain constant).

First, we assumed that the vasculature of the lung behaves uniformly in the sense that the proportionate change in regional blood flow in response to a regional change in P[a]{.smallcaps}~CO~2~~ is the same as the proportionate global change in blood flow in response to a global change in the mean P[a]{.smallcaps}~CO~2~~ (assuming conditions of constant perfusion pressure in each case). Assuming that P[a]{.smallcaps}~CO~2~~ is uniform throughout the lung, we may write (using P~CO~2~~ as an abbreviation for P[a]{.smallcaps}~CO~2~~ in the following equations): $$\left( \frac{\partial\ln\overset{˙}{q}}{\partial\text{P}_{\text{A}_{\text{CO}_{2}}}} \right)_{\Delta\text{Pmax}} = \left( \frac{\partial\ln\overset{˙}{Q}}{\partial\text{P}_{\text{A}_{\text{CO}_{2}}}} \right)_{\Delta\text{Pmax}}$$

The principal difficulty in obtaining (∂lnQ̇/∂P[co]{.smallcaps}~2~)~ΔPmax~ in *[Eq. 4](#FD4){ref-type="disp-formula"}* from experimental measurements in humans in vivo is that this differential contains the constraint that perfusion pressure (ΔPmax) remains constant. This is not something that can be achieved experimentally in humans. However, we show below that (∂lnQ̇/∂P[co]{.smallcaps}~2~)~ΔPmax~ can be written as a function of three variables that are accessible experimentally in humans: two of these are measured directly in the experimental component of this study \[vide infra, δ(ΔPmax)/δP[co]{.smallcaps}~2~ and δQ̇/δP[co]{.smallcaps}~2~ of *[Eq. 10](#FD10){ref-type="disp-formula"}*\] and a third variable \[vide infra, (∂ΔPmax/∂Q̇)~P[co]{.smallcaps}~2~~ of *[Eq. 10](#FD10){ref-type="disp-formula"}*\] that has been obtained in a previous study. A secondary difficulty (for which we accept some approximation) is that the distribution of P[a]{.smallcaps}~CO~2~~ throughout the lung is not completely uniform.

We proceeded by noting that, for the lung as a whole, ΔPmax may be regarded as a function of both Q̇ and P[a]{.smallcaps}~CO~2~~. Consequently, an increment in ΔPmax \[δ(ΔPmax)\] may be considered to arise through an increase in flow at constant vascular tone and an increase in vascular tone at constant flow, as follows: $$\partial\left( {\Delta\text{Pmax}} \right)\left( \frac{\partial\Delta\text{Pmax}}{\partial\overset{˙}{Q}} \right)_{\text{PCO}_{2}}\partial\overset{˙}{Q} + \left( \frac{\partial\Delta\text{Pmax}}{\partial\text{P}_{\text{CO}_{2}}} \right)_{\overset{˙}{Q}}\partial\text{P}_{\text{CO}_{2}}$$

To obtain a general expression containing the partial derivative (∂Q̇/∂P[co]{.smallcaps}~2~)~ΔPmax~ in *[Eq. 4](#FD4){ref-type="disp-formula"}*, we can set δ(ΔPmax) = 0 in *[Eq. 5](#FD5){ref-type="disp-formula"}* and divide through by δP[co]{.smallcaps}~2~ to obtain: $$0 = \left( \frac{\partial\Delta\text{Pmax}}{\partial\overset{˙}{Q}} \right)_{\text{PCO}_{2}}\left( \frac{\partial\overset{˙}{Q}}{\partial\text{P}_{\text{CO}_{2}}} \right)_{\Delta\text{Pmax}} + \left( \frac{\partial\Delta\text{Pmax}}{\partial\text{P}_{\text{CO}_{2}}} \right)_{\overset{˙}{Q}}$$ or$$\left( \frac{\partial\ln\overset{˙}{Q}}{\partial\text{P}_{\text{CO}_{2}}} \right)_{\Delta\text{P}\max} = - \frac{1}{\overset{˙}{Q}}\left( \frac{\partial\Delta\text{P}\max}{\partial\text{P}_{\text{CO}_{2}}} \right)_{\overset{˙}{Q}}\overset{˙}{/}\left( \frac{\partial\Delta\text{P}\max}{\partial\overset{˙}{Q}} \right)_{\text{PCO}_{2}}$$

Combining *[Eqs. 2](#FD2){ref-type="disp-formula"}, [3](#FD3){ref-type="disp-formula"}, [4](#FD4){ref-type="disp-formula"}*, and *[7](#FD7){ref-type="disp-formula"}* yields: $$\text{H=}\left( \frac{\overset{˙}{v}}{\overset{˙}{q}} \right)\left( \frac{1}{\overset{˙}{Q}} \right)\left( \frac{\partial\Delta\text{P}\max}{\partial\text{P}_{\text{CO}_{2}}} \right)_{\overset{˙}{Q}}/\left( \frac{\partial\Delta\text{P}\max}{\partial\overset{˙}{Q}} \right)_{\text{PCO}_{2}}$$

A rearrangement of *[Eq. 5](#FD5){ref-type="disp-formula"}* yields: $$\left( \frac{\partial\Delta\text{P}\max}{\partial\text{P}_{\text{CO}_{2}}} \right)_{\overset{˙}{Q}} = \left( \frac{\delta\left( {\Delta\text{P}\max} \right)}{\partial\text{P}_{\text{CO}_{2}}} \right) - \left( \frac{\delta\overset{˙}{Q}}{\delta\text{P}_{\text{CO}_{2}}} \right)\left( \frac{\partial\Delta\text{P}\max}{\delta\overset{˙}{Q}} \right)_{\text{PCO}_{2}}$$

Combining *[Eqs. 8](#FD8){ref-type="disp-formula"}* and [9](#FD9){ref-type="disp-formula"} yields: $$\text{H=}\left( \frac{\overset{˙}{v}}{\overset{˙}{q}} \right)\left( \frac{1}{\overset{˙}{Q}} \right)\left\lbrack \left( \frac{\delta\left( {\Delta\text{P}\max} \right)}{\partial\text{P}_{\text{CO}_{2}}} \right) \right\rbrack/\left( \frac{\partial\Delta\text{P}\max}{\partial\overset{˙}{Q}} \right)_{\text{PCO}_{2}} - \left( \frac{\delta\overset{˙}{Q}}{\delta\text{P}_{\text{CO}_{2}}} \right)$$

In *[Eq. 10](#FD10){ref-type="disp-formula"}*, the term (∂ΔPmax/∂Q̇)~P[co]{.smallcaps}~2~~ may be given a value of 0.6 Torr·l^−1^·min derived from the literature ([@B3]). The terms prefaced by δ now reflect values for the whole lung when all three variables (ΔPmax, Q̇, and P[co]{.smallcaps}~2~) change simultaneously and may be estimated from the measurements made in *Experimental Study*.

### Estimation of −K for CO~2~: effects of changes in v̇/q̇ on regional P[a]{.smallcaps}~CO~2~~.

Using the principles of mass balance, we may equate the CO~2~ exchange for the blood and gas phases for a region of the lung as follows: $$\overset{˙}{v} \cdot \text{P}_{\text{CO}_{2}}/\text{Patm=}\overset{˙}{q} \cdot \left( {\text{C}{\overline{v}}_{\text{CO}_{2}} - \text{Cec}_{\text{CO}_{2}}} \right)$$ where Cv̄~CO~2~~ is systemic mixed venous (pulmonary arterial) CO~2~ concentration, Cec~CO~2~~ is pulmonary end-capillary CO~2~ concentration, and Patm is atmospheric pressure. Assuming that the dissociation curve for CO~2~ may be regarded as linear over the physiological range in the form (Cv̄~CO~2~~ − Cec~CO~2~~) = β (Pv̄~CO~2~~ − P[co]{.smallcaps}~2~), *[Eq. 11](#FD11){ref-type="disp-formula"}* may be written: $$\text{P}_{\text{CO}_{2}} = \frac{\beta \cdot \text{Patm}}{\beta \cdot \text{Patm+}\left( {\overset{˙}{v}\text{/}\overset{˙}{q}} \right)} \cdot \text{P}{\overline{v}}_{\text{CO}_{2}}$$

Differentiating with respect to v̇/q̇, assuming no change in Pv̄~CO~2~~, and noting that the resulting derivative equals −K ([Fig. 1](#F1){ref-type="fig"}) yields: $$- \text{K=}\frac{\text{dP}_{\text{CO}_{2}}}{\text{d}\left( {\overset{˙}{v}\text{/}\overset{˙}{q}} \right)} = \frac{- \beta \cdot \text{Patm}}{\left( {\beta \cdot \text{Patm+}\overset{˙}{v}\text{/}\overset{˙}{q}} \right)^{2}} \cdot \text{P}{\overset{˙}{v}}_{\text{CO}_{2}}$$

It is important to note the significance of the assumption of no change in Pv̄~CO~2~~ in the derivation of *[Eq. 13](#FD13){ref-type="disp-formula"}*. This is equivalent to assuming that the local region of the lung in which the disturbance of v̇/q̇ occurs is small enough for it not to lead to any change in the composition of systemic mixed venous (pulmonary arterial) blood. This completes the calculation of the effect on regional P[a]{.smallcaps}~CO~2~~ of a given change in v̇/q̇.

### Overall loop gain for CO~2~.

The closed-loop gain (−K × H) is given by the product of the sensitivities of the two components of the loop (*[Eqs. 10](#FD10){ref-type="disp-formula"}* and *[13](#FD3){ref-type="disp-formula"}*) and may be written: $$- \text{KH=}\frac{- \beta \cdot \text{PatmP}{\overset{˙}{v}}_{\text{CO}_{2}}\left( {\overset{˙}{v}\text{/}\overset{˙}{q}} \right)}{\left( {\beta \cdot \text{Patm+}\overset{˙}{v}\text{/}\overset{˙}{q}} \right)^{2}}\left\lbrack {\left( \frac{\delta\left( {\Delta\text{P}\max} \right)}{\delta\text{P}_{\text{CO}_{2}}} \right)\frac{1}{0.6} - \left( \frac{\delta\overset{˙}{Q}}{\delta\text{P}_{\text{CO}_{2}}} \right)} \right\rbrack$$

### Significance of overall loop gain for CO~2~.

In the closed-loop setting, an initial disturbance in P[a]{.smallcaps}~CO~2~~ of magnitude *h*~*0*~ is attenuated by the feedback system, such that the final steady-state disturbance, *h*~*1*~, is given by the relationship:$$h_{1} = h_{0} - \text{KH}h_{1}$$

This relationship is depicted graphically in [Fig. 1*B*](#F1){ref-type="fig"}. It follows from *[Eq. 15](#FD15){ref-type="disp-formula"}* that the ratio of disturbance in regional P[a]{.smallcaps}~CO~2~~ between the closed and open loop situations is given by:$$h_{1}/h_{0} = 1/\left( {1 + \text{KH}} \right)$$

From this, it is possible to define a measure of control efficiency, *E*, according to *[Eq. 1](#FD1){ref-type="disp-formula"}* as:$$E = 100\left\lbrack {1 - 1/\left( {1 + \text{KH}} \right)} \right\rbrack$$

For a feedback system that is completely ineffective (KH = 0), *E* = 0%. For a feedback system that exerts total control (KH tends to infinity), *E* = 100%.

Theory for O~2~
---------------

The calculation of closed-loop gain for hypoxic pulmonary vasoconstriction proceeds in a reasonably analogous manner to that for hypercapnic pulmonary vasoconstriction.

### Estimation of H for O~2~: effect of changes in regional P[a]{.smallcaps}~O~2~~ on v̇/q̇.

The derivation of the expression for H for O~2~ proceeds in a completely analogous manner to that for CO~2~. The resulting equation (equivalent to *[Eq. 10](#FD10){ref-type="disp-formula"}*) is as follows:$$\text{H=}\left( \frac{\overset{˙}{v}}{\overset{˙}{q}} \right)\left( \frac{1}{\overset{˙}{Q}} \right)\left\lbrack {\left( \frac{\delta\left( {\Delta\text{P}\max} \right)}{\partial\text{P}_{\text{O}_{2}}} \right)/\left( \frac{\partial\Delta\text{P}\max}{\partial\overset{˙}{Q}} \right)_{\text{Po}_{2}} - \left( \frac{\delta\overset{˙}{Q}}{\delta\text{P}_{\text{O}_{2}}} \right)} \right\rbrack$$

In *[Eq. 18](#FD18){ref-type="disp-formula"}*, the term (∂ΔPmax/∂Q̇)~P[o]{.smallcaps}~2~~ may be given the same value from the literature of 0.6 Torr·l^−1^·min^−1^ ([@B3]) as has been used for CO~2~. However, a complication in the case for O~2~ is that neither δΔPmax/δP[o]{.smallcaps}~2~ nor δQ̇/δP[o]{.smallcaps}~2~ is a constant across the physiological range of interest for P[o]{.smallcaps}~2~. However, in the case of the pulmonary vascular response to P[o]{.smallcaps}~2~, it has been found that the response is reasonably linear if it is related to the saturation (S) of hemoglobin that corresponds to the P[o]{.smallcaps}~2~ values of interest ([@B22]). Severinghaus provides a convenient relationship for humans for converting values of P[o]{.smallcaps}~2~ to values for S ([@B32]): S = {\[(P[o]{.smallcaps}~2~^3^ + 150 P[o]{.smallcaps}~2~)^−1^ × 23,400\] + 1}^−1^ (with P[o]{.smallcaps}~2~ in Torr). Using this relationship, we can estimate from the literature ([@B39]) a value for δ(ΔPmax)/δS of −0.461 Torr/%. We may then estimate δ(ΔPmax)/δP[o]{.smallcaps}~2~ for any particular value for P[o]{.smallcaps}~2~ using the relationship:$$\left( \frac{\delta\left( {\Delta\text{P}\max} \right)}{\partial\text{P}_{\text{O}_{2}}} \right) = \frac{\text{ds}}{\text{dP}_{\text{O}_{2}}}\left( \frac{\delta\left( {\Delta\text{P}\max} \right)}{\partial\text{S}} \right)$$where dS/dP[o]{.smallcaps}~2~ is obtained by differentiating the expression given by Severinghaus ([@B32]).

A similar approach has been adopted for δQ̇/δP[o]{.smallcaps}~2~. From the literature ([@B39]), we estimate a value for δQ̇/δS of −0.07 l·min^−1^·%^−1^. We may then estimate δQ̇/δP[o]{.smallcaps}~2~ for any particular value for P[o]{.smallcaps}~2~ using the relationship:$$\left( \frac{\delta\overset{˙}{Q}}{\delta\text{P}_{\text{O}_{2}}} \right) = \frac{\text{ds}}{\text{dP}_{\text{O}_{2}}}\left( \frac{\delta\overset{˙}{Q}}{\delta\text{S}} \right)$$

### Estimation of −K for O~2~: effects of changes in v̇/q̇ on regional P[a]{.smallcaps}~O~2~~.

Unlike the case of CO~2~, the equation relating the exchange of O~2~ in blood and gas phases has to incorporate the presence of O~2~ in the inspired gas and is given by ([@B20]):$$\overset{˙}{v} \cdot \left( {\text{PI}_{\text{O}_{2}} - \text{P}_{\text{O}_{2}}} \right)/\text{Patm=}\overset{˙}{q} \cdot \left( {\text{Cec}_{\text{O}_{2}} - \text{C}{\overline{v}}_{\text{O}_{2}}} \right)$$

where P[i]{.smallcaps}~O~2~~ is inspired P[o]{.smallcaps}~2~, Cv̄~O~2~~ is systemic mixed venous (pulmonary arterial) O~2~ concentration, and Cec~O~2~~ is pulmonary end-capillary O~2~ concentration.

Cec~O~2~~ is a function of regional P[a]{.smallcaps}~O~2~~ as follows ([@B20]):$$\text{Cec}_{\text{O}_{2}} = \alpha \cdot \text{P}_{\text{O}_{2}} + \text{c} \cdot \text{Hb} \cdot \text{S}$$where Hb is the concentration of hemoglobin in blood, c is the maximum binding capacity of hemoglobin, and α is the solubility in blood of molecular O~2~. Values used were Hb = 157 g/l ([@B36]), c = 1.34 × 10^−3^ l ([stpd]{.smallcaps})/g ([@B32]), and α = 3.1 × 10^−5^ l ([stpd]{.smallcaps})·l^−1^·Torr^−1^ ([@B32]).

Substituting for Cec~O~2~~ from *[Eq. 22](#FD22){ref-type="disp-formula"}* into *[Eq. 21](#FD21){ref-type="disp-formula"}*, we obtain$$\frac{\overset{˙}{v}}{\overset{˙}{q}} = \left( \frac{\alpha \cdot \text{P}_{\text{O}_{2}} + \text{c} \cdot \text{Hb} \cdot \text{S} - \text{C}{\overline{v}}_{\text{O}_{2}}}{\text{PI}_{\text{O}_{2}} - \text{P}_{\text{O}_{2}}} \right)\text{Patm}$$

A numerical value for Cv̄~O~2~~ in this expression may be obtained using the same function that relates Cec~O~2~~ to P[o]{.smallcaps}~2~ (*[Eq. 22](#FD22){ref-type="disp-formula"}*) and assuming a standard value for systemic mixed venous S of 0.711 ([@B36]), which corresponds to a P[o]{.smallcaps}~2~ of 37 Torr ([@B32]). As in the handling of CO~2~, we are again assuming that the local region of the lung in which the disturbance of v̇/q̇ occurs is small enough for it not to lead to any change in the composition of systemic mixed venous (pulmonary arterial) blood.

Differentiating *[Eq. 23](#FD23){ref-type="disp-formula"}* with respect to P[o]{.smallcaps}~2~ and inverting both sides of the relation, we obtain$$- \text{K=}\frac{\text{dP}_{\text{O}_{2}}}{\text{d}\left( {\overset{˙}{v}\text{/}\overset{˙}{q}} \right)} = \frac{1}{\text{Patm}} \times \left\lbrack \frac{\left( {\text{PI}_{\text{O}_{2}} - \text{P}_{\text{O}_{2}}} \right)^{2}}{\left( {\text{PI}_{\text{O}_{2}} - \text{P}_{\text{O}_{2}}} \right)\left( {\alpha + c \cdot \text{Hb}\frac{\text{ds}}{\text{dP}_{\text{O}_{2}}}} \right) + \alpha \cdot \text{P}_{\text{O}_{2}} + \text{c} \cdot \text{Hb} \cdot \text{S} - \text{C}{\overline{v}}_{\text{O}_{2}}} \right\rbrack$$

### Overall loop gain for O~2~.

The closed-loop gain (−K × H) is given by the product of the sensitivities of the two components of the loop (*[Eqs. 18](#FD8){ref-type="disp-formula"}* and *[24](#FD4){ref-type="disp-formula"}*) and, noting that we may substitute for the term v̇/q̇ using *[Eq. 23](#FD23){ref-type="disp-formula"}*, is given by $$- \text{KH\ =}\frac{\frac{1}{\overset{˙}{Q}}\left\lbrack {\left( \frac{\delta\left( {\Delta\text{P}\max} \right)}{\delta\text{P}_{\text{O}_{2}}} \right)\frac{1}{0.6} - \left( \frac{\delta\overset{˙}{Q}}{\delta\text{P}_{\text{O}_{2}}} \right)} \right\rbrack}{\left\lbrack {\left( \frac{\alpha + c \cdot \text{Hb}\frac{\text{ds}}{\text{dP}_{\text{O}_{2}}}}{\alpha \cdot \text{P}_{\text{O}_{2}} + \text{c} \cdot \text{Hb} \cdot \text{S} - \text{C}{\overset{˙}{v}}_{\text{O}_{2}}} \right) + \frac{1}{\text{PI}_{\text{O}_{2}} - \text{P}_{\text{O}_{2}}}} \right\rbrack}$$

It should be noted that the closed-loop gain for O~2~ (*[Eq. 25](#FD25){ref-type="disp-formula"}*) is given as a function of P[a]{.smallcaps}~O~2~~, whereas that for CO~2~ (*[Eq. 14](#FD14){ref-type="disp-formula"}*) is given as a function of v̇/q̇. However, v̇/q̇ and P[a]{.smallcaps}~O~2~~ are related to each other through *[Eq. 23](#FD23){ref-type="disp-formula"}*; therefore, a value for P[a]{.smallcaps}~O~2~~ that corresponds to any particular value for v̇/q̇ may be obtained through numerical solution of this equation.

The measure of overall efficiency of control, *E*, is analogous to that for CO~2~, as given in *[Eq. 17](#FD17){ref-type="disp-formula"}*.

Theory for CO~2~ and O~2~ Combined
----------------------------------

Assuming that, for relatively small changes, any nonlinear interaction between the combined stimuli of CO~2~ and O~2~ can be neglected, then the combined efficiency of regulation by both CO~2~ and O~2~ can be derived in an additive manner. The combined closed-loop gain, −Gtot, is given by $$- \text{Gtot}\, = \, - \left( \text{KH} \right)_{\text{CO}_{2}} - \left( \text{KH} \right)_{\text{O}_{2}}$$ where −(KH)~CO~2~~ and −(KH)~O~2~~ are the individual closed-loop gains, respectively, for CO~2~ and O~2~.

The measure of overall control efficiency (*E*~tot~) is given by $$\text{Etot}\, = \,{100}\left( {\text{1} - 1/\left( {1 + \text{Gtot}} \right)} \right)$$

Experimental Study
------------------

The experimental methods described in this section were those used to estimate values for the two following coefficients of *[Eq. 14](#FD14){ref-type="disp-formula"}*: δ(ΔPmax)/δP[co]{.smallcaps}~2~ and δQ̇/δP[co]{.smallcaps}~2~. The coefficients apply to the situation in which P[a]{.smallcaps}~CO~2~~ is varied and both ΔPmax and Q̇ are allowed to change freely. As explained in the theory above, *[Eq. 14](#FD14){ref-type="disp-formula"}* applies to a model of the lung that is uniform with respect to alveolar gas composition. This condition is not completely fulfilled in healthy volunteers (or others); therefore, we must accept some (modest) degree of inaccuracy in our estimates arising from this approximation. The experimental study also allowed the speed of response of ΔPmax to variations in P[a]{.smallcaps}~CO~2~~ to be assessed to ensure that this was sufficiently rapid for effective control through CO~2~ to occur.

### Volunteers.

Twelve healthy volunteers (6 women and 6 men, age 26.6 ± 2.9 years, means ± SD) participated in the present study. Volunteers were evaluated using Doppler echocardiography and were included in the study, provided that ultrasound images could be obtained easily. Female volunteers were asked to participate only during the first 14 days of their menstrual cycle. Informed written consent was obtained from all volunteers on each experimental day. The study was approved by the Central Oxford Research Ethics Committee and performed in accordance with the Declaration of Helsinki.

### Protocols.

In the protocols described in the following paragraph, euoxic eucapnia refers to the condition in which end-tidal P[o]{.smallcaps}~2~ (P[et]{.smallcaps}~O~2~~) is maintained at 100 Torr and end-tidal P[co]{.smallcaps}~2~ (P[et]{.smallcaps}~CO~2~~) is maintained either at, or just above (+1--2 Torr), each volunteer\'s normal value. Euoxic hypercapnia refers to the condition in which P[et]{.smallcaps}~O~2~~ is maintained at 100 Torr and P[et]{.smallcaps}~CO~2~~ is maintained 10 Torr above each volunteer\'s normal value. Euoxic hypocapnia refers to the condition in which P[et]{.smallcaps}~O~2~~ is maintained at 100 Torr and P[et]{.smallcaps}~CO~2~~ is maintained 10 Torr below each volunteer\'s normal value.

Each volunteer undertook three different protocols separated by at least 48 h from each other. The "hypercapnia protocol" consisted of 5 min of euoxic eucapnia, followed by 25 min of euoxic hypercapnia, followed by a further 5 min of euoxic eucapnia. The "hypocapnia protocol" consisted of 5 min of euoxic eucapnia, followed by 25 min of euoxic hypocapnia, followed by a further 5 min of euoxic eucapnia. The "control protocol" consisted of 35 min of euoxic eucapnia.

Each protocol was performed twice within 24 h (with a separation of more than 4 h). This was done so that almost continuous Doppler measurements of ΔPmax could be obtained during one repeat of the protocol and almost continuous measurements of Q̇ could be obtained during the other repeat of the protocol. Such measurements could not be obtained simultaneously. The order of the two measurements was varied; half of the volunteers always had ΔPmax measured first, and the other half had Q̇ measured first.

### Control of end-tidal gases.

Volunteers lay in a semi-left lateral position and breathed through a mouthpiece while wearing a nose clip. The partial pressures of the inspired gases were adjusted breath-by-breath using an end-tidal forcing system so that the desired end-tidal values were maintained, as described previously ([@B29]). In both the hypercapnia protocol and control protocol, breathing was spontaneous. In the hypocapnia protocol, voluntary hyperventilation was used.

### Voluntary hyperventilation.

Throughout the hypocapnia protocol, volunteers were asked to breathe to a predetermined tidal volume and respiratory frequency. An oscilloscope was used to help volunteers adjust their tidal volume by following a line to a specific point on the screen during inspiration. An audible signal was used to maintain regular breathing. Before the beginning of the experiment, a level of hyperventilation was identified for each volunteer that lowered the volunteer\'s P[et]{.smallcaps}~CO~2~~ to slightly more than 10 Torr below their normal value while they breathed air. This level of hyperventilation was used during the succeeding experiment. During the experiment, CO~2~ was added to inspired gas to produce the desired profile in P[et]{.smallcaps}~CO~2~~ using the end-tidal forcing technique.

### Echocardiography.

Echocardiographic measurements were performed using a Hewlett Packard Sonos 5500 ultrasound machine with an S4 two-dimensional transducer (2--4 MHz). Volunteers were examined while they were in a recumbent position (lying on their left side) on a suitably modified couch. A super-VHS video recorder was used to store spectral waveforms for the entire duration of each experiment. The tapes were played back at a later time for spectral waveform analyses. For each measurement point, averages were obtained from three or more envelopes recorded at end-expiration or as close as possible to it. Using this approach, we could average measurements for ΔPmax for intervals as small as 30 s. Heart rate (HR) and a respiratory waveform were also recorded.

### Tricuspid valve maximum pressure difference (ΔPmax).

In a majority of people, ultrasound can be used to detect a regurgitant jet through the tricuspid valve. We identified volunteers in whom this jet could be detected and measured the velocity (*v*) with which it leaves the right ventricle and enters the right atrium. On the assumption that the jet can be regarded as steady, Bernoulli\'s equation (*[Eq. 28](#FD28){ref-type="disp-formula"}*) can be used to relate ΔPmax to *v*: $$\Delta\text{P}\max = \rho\nu^{2}/2$$ where ρ is the density of blood. We have previously shown that ΔPmax provides a sensitive index of the pulmonary vascular response to hypoxia in healthy humans while changing little with Q̇ in the absence of changes in the composition of alveolar gas ([@B3]). In accord with that study, we initially anticipated that only ∼5% of any change in ΔPmax with hypercapnia or hypocapnia would be attributable to any concurrent change in Q̇. On the basis of these findings and following earlier studies ([@B2], [@B16]), we take ΔPmax to be our primary measure of the speed and intensity of action of hyper/hypocapnia on pulmonary vascular smooth muscle. It is important to note, however, that the assumptions underlying *[Eq. 14](#FD14){ref-type="disp-formula"}* require only that, for the lung as a whole, ΔPmax may be regarded as a function of both Q̇ and P[a]{.smallcaps}~CO~2~~. The fact that ΔPmax is influenced to a more minor degree by Q̇ than by P[a]{.smallcaps}~CO~2~~ in healthy volunteers may be of value in some applications but is not a requirement of our study.

ΔPmax was measured using a standard technique ([@B27]). An apical four-chamber view of the heart was used to observe the tricuspid valve in two dimensions; color Doppler format was then used to detect the regurgitant jet. After alignment with the Doppler beam, continuous-wave spectral analysis at a sweep speed of 50 mm/s was used to record the velocity profile of the jet. During analysis, the maximal velocity of the jet was measured using an electronic caliper tool integrated with the echocardiography machine. Each measurement of ΔPmax was made from at least three velocity profiles taken toward the end of expiration.

### Cardiac output.

An apical five-chamber view of the heart was used with Doppler mode to identify flow through the aortic valve during systole. Using pulsed-wave spectral mode at a screen sweep speed of 100 mm/s, we obtained the velocity profile of the aortic flow. Doppler sampling of the flow was taken immediately below the orifice of the aortic valve. The flow was quantified automatically using the velocity time integral, which is the mean distance through which blood travels in the outflow tract during ventricular contraction. Each measurement of velocity time integral was made from at least three velocity profiles taken toward the end of expiration.

The diameter of the aortic valve was measured from a parasternal long axis view, and the aortic valve area (*A*) was calculated. Stroke volume (SV) was calculated from velocity time integral × *A*; Q̇ was calculated from SV multiplied by HR. Measurements of Q̇, SV, and HR are presented at minute intervals.

### Modeling.

Our results were quantified through the parameter values of simple models that describe the acute responses of the variables ΔPmax, SV, HR, and Q̇ to hypercapnia and hypocapnia. The parameter values for the models were obtained through a process of fitting the model to the experimental data. Each model has one parameter for the value of the variable under conditions of steady eucapnia (*M*), a second parameter for the sensitivity of the response (*G*) to hypercapnia or hypocapnia (depending on protocol), and a third parameter that gives the time constant (τ for the response). The model is given by: $$y_{n + 1} = \left\{ {M + G \cdot \left\lbrack {\text{P}_{\text{CO}_{2{(\text{n})}}} - \text{P}} \right\rbrack} \right\} - \left\{ {\left\lbrack {M + G \cdot \left( {\text{P}_{\text{CO}_{2{(\text{n})}}} - \text{P}} \right)} \right\rbrack - y_{n}} \right\} \cdot \exp^{}\left( {- \Delta t/\tau} \right)$$ where *P* is the value for P[et]{.smallcaps}~CO~2~~ during eucapnia, P[co]{.smallcaps}~2*(n)*~ is the value for P[et]{.smallcaps}~CO~2~~ at the *n*th time point, Δ*t* is the time interval between the data points (either 0.5 min or 1 min), and *y* variously represents one of the four variables (ΔPmax, SV, HR, and Q̇). For each volunteer, the model was fitted to the data for each repeat of the hypercapnia and hypocapnia protocols using a program written in Matlab 6.1.

Statistical Analysis
--------------------

For the measured variables, repeated-measures ANOVA (rmANOVA) was undertaken to determine whether there was an interaction between time and protocol. A separate test of rmANOVA was then performed on the data from just the control protocol to check that time did not have a significant effect in this protocol. Ordinary, univariate, ANOVA was used to assess the significance of differences between protocols for the parameter estimates for the models.

RESULTS
=======

The first part of the [results]{.smallcaps} relates to our main objective, which is to present the efficiency of feedback regulation of the alveolar gases by the pulmonary vasculature. For CO~2~, these calculations require experimental estimates of the coefficients δ(ΔPmax)/δP[co]{.smallcaps}~2~ and δQ̇/δP[co]{.smallcaps}~2~. The detailed results from the experimental study that provide these coefficients are given in the second part of the [results]{.smallcaps}. As a secondary objective, these experimental results provide time constants for the speed of the pulmonary vascular response to CO~2~.

Estimates of Closed-Loop Gain and Efficiency of Control
-------------------------------------------------------

The results from this part of the study are presented in [Fig. 2](#F2){ref-type="fig"}, in which the calculated variables are shown as a function of v̇/q̇. The range of values of v̇/q̇ was chosen to be 0.1--10 to encompass those anticipated in the healthy human lung ([@B40]) and presented on a logarithmic scale.

![*Top*: P[a]{.smallcaps}~CO~2~~ and P[a]{.smallcaps}~O~2~~ as a function of regional v̇/q̇. *Middle*: feedback loop gains for the regulation of regional v̇/q̇ by hypercapnic and hypoxic pulmonary vasoconstriction. *Bottom*: efficiencies of regulation of regional v̇/q̇ by hypercapnic and hypoxic pulmonary vasoconstriction. Dashed lines, responses relating to CO~2~; dotted lines, responses relating to O~2~; solid lines, combined responses to both CO~2~ and O~2~. Note that the regulatory effect of O~2~ is greater than that for CO~2~ at low values for v̇/q̇, that the regulatory effect of CO~2~ is greater than that for O~2~ at higher values of v̇/q̇, and that the total regulatory efficiency remains relatively constant over the range of values displayed for v̇/q̇.](zdg0051090370002){#F2}

[Figure 2](#F2){ref-type="fig"}, *top*, shows P[a]{.smallcaps}~O~2~~ and P[a]{.smallcaps}~CO~2~~ obtained from *[Eqs. 21](#FD1){ref-type="disp-formula"}* and *12*, respectively. The range of values for P[a]{.smallcaps}~O~2~~ is from 42 to 145 Torr, whereas that for P[a]{.smallcaps}~CO~2~~ is from 16 to 46 Torr. [Figure 2](#F2){ref-type="fig"}, *middle*, shows the steady-state closed-loop gains for O~2~ and CO~2~ and the combination of O~2~ and CO~2~ together, as calculated, respectively, from *[Eqs. 25](#FD5){ref-type="disp-formula"}, [14](#FD14){ref-type="disp-formula"}*, and *26.* [Figure 2](#F2){ref-type="fig"}, *bottom*, shows the efficiency of feedback control for O~2~ and CO~2~ and the combination of O~2~ and CO~2~ together, as calculated from *[Eq. 17](#FD17){ref-type="disp-formula"}* for O~2~ and CO~2~ and from *[Eq. 27](#FD27){ref-type="disp-formula"}* for the combination of O~2~ and CO~2~.

The efficiency for combined regulation by CO~2~ and O~2~ remains fairly close to 60% across the entire range of values shown for v̇/q̇. However, the individual contributions from CO~2~ and O~2~ vary markedly with v̇/q̇. Whereas O~2~ has a greater regulatory effect at the lower values of v̇/q̇, CO~2~ has a greater effect at values of v̇/q̇ above ∼0.65. As the average value for ratio of ventilation to perfusion is ∼0.9--1.0 ([@B40]), the result suggests that the regulatory effects of CO~2~ may be greater than those of O~2~ throughout much of the lung; around the mean ratio the effects of CO~2~ may be twofold greater than those of O~2~.

Experimental Study
------------------

### Gas control.

[Figure 3](#F3){ref-type="fig"} shows the values for inspired and end-tidal P[o]{.smallcaps}~2~ and P[co]{.smallcaps}~2~ for all three protocols. Separate graphs are shown for the repetitions of each protocol for the different Doppler measurements (ΔPmax and Q̇), showing that nearly identical conditions were successfully achieved. In the hypercapnia protocol, a very quick transition into and out of hypercapnia was achieved with a step duration of \<30 s. The transition into and out of hypocapnia in the hypocapnia protocol was slower, with a step duration of ∼2 min. During the control protocol, P[et]{.smallcaps}~CO~2~~ was maintained very constant, within ∼1 Torr of the normal air-breathing values. Ventilations during the initial 5-min periods of the hypercapnia, hypocapnia, and control protocols were, respectively, 12.6 (SD 2.7), 22.9 (SD 5.7), and 12.0 (SD 2.8) l/min. Mean ventilations during the 20-min periods of hypercapnia, hypocapnia, or control for the three protocols were, respectively, 35.6 (SD 9.0), 23.8 (SD 5.4), and 12.6 (SD 2.4) l/min.

![Composition of respired gas during each of the 3 main protocols. *Top*: hypercapnia protocol consisting of a 25-min period of euoxic hypercapnia preceded and followed by a 5-min period of euoxic eucapnia. Ventilation was spontaneous throughout. *Middle*: hypocapnia protocol consisting of a 25-min period of euoxic hypocapnia preceded and followed by a 5-min period of euoxic eucapnia. The volunteers undertook voluntary hyperventilation throughout. *Bottom*: control protocol consisting of a 35-min period of euoxic eucapnia. Ventilation was spontaneous throughout. *Left*: values during the determination of the maximum pressure difference across the tricuspid valve (ΔPmax). *Right*: values during the determination of cardiac output. Results show inspired P[co]{.smallcaps}~2~ (P[i]{.smallcaps}~CO~2~~; triangles), inspired P[o]{.smallcaps}~2~ (P[i]{.smallcaps}~O~2~~; diamonds), end-tidal P[co]{.smallcaps}~2~ (P[et]{.smallcaps}~CO~2~~; circles), and end-tidal P[o]{.smallcaps}~2~ (P[et]{.smallcaps}~O~2~~; squares). Closed symbols indicate periods of either hypercapnia or hypocapnia; open symbols indicate periods of eucapnia. Data are means for 12 subjects; error bars are ± SE. Note that, in the hypercapnia protocol, P[i]{.smallcaps}~CO~2~~ is close to 40 Torr during euoxic hypercapnia, which coincidentally is very close to P[et]{.smallcaps}~CO~2~~ before and after this period.](zdg0051090370003){#F3}

### Pulmonary vascular responses to hypercapnia and hypocapnia.

ΔPmax responses for all three protocols are shown in [Fig. 4](#F4){ref-type="fig"}. ΔPmax increased by ∼6 Torr with hypercapnia and decreased by ∼4 Torr with hypocapnia. Both responses were significantly different from control responses (rmANOVA, *P* \< 0.001). The effects of hypercapnia and hypocapnia were quickly reversed when euoxic eucapnia was restored. The control experiment revealed no changes in ΔPmax for the entire duration of the exposure.

![Tricuspid valve maximum pressure difference (ΔPmax) during the 3 main protocols: hypercapnia (circles), hypocapnia (squares), and control (triangles). Closed symbols indicate measurements made under hypercapnic (hypercapnia protocol) or hypocapnic (hypocapnia protocol) conditions; open symbols indicate measurements made under eucapnic conditions. Data are means for 12 subjects; error bars are ± SE. ΔPmax was significantly affected by both hypercapnia and hypocapnia compared with control (*P* \< 0.001, rmANOVA).](zdg0051090370004){#F4}

### Q̇, SV, and HR.

The responses of Q̇ and its components (SV and HR) are shown in [Fig. 5](#F5){ref-type="fig"}. Baseline values for these three variables were higher in the hypocapnia protocol than in the other two protocols. In the hypocapnia protocol, ventilation was elevated throughout by volunteers who performed voluntary hyperventilation, whereas this was not the case in the other two protocols. During hypercapnia, Q̇ increased by ∼1 l/min (∼22%, rmANOVA, *P* \< 0.001), SV increased by ∼10 ml (∼12%, rmANOVA, *P* \< 0.04), and HR increased by ∼6 beats/min (∼11%, rmANOVA, *P* \< 0.003) when compared with baseline. During hypocapnia, Q̇ decreased by ∼0.8 l/min (∼16%, rmANOVA, *P* \< 0.001), SV decreased by ∼7 ml (∼8%, rmANOVA, *P* \< 0.001), and HR decreased by ∼5 beats/min (∼8%, rmANOVA, *P* \< 0.002) when compared with baseline.

![Cardiac output (*top*), stroke volume (*middle*), and heart rate (*bottom*) during the 3 main protocols: hypercapnia (circles), hypocapnia (squares), and control (triangles). Closed symbols indicate measurements made under hypercapnic (hypercapnia protocol) or hypocapnic (hypocapnia protocol) conditions; open symbols indicate measurements made under eucapnic conditions. Data are means for 12 subjects; error bars are ± SE.](zdg0051090370005){#F5}

### Model parameters: ΔPmax.

[Figure 6](#F6){ref-type="fig"} illustrates a typical model fit to the data for one volunteer, and [Table 1](#T1){ref-type="table"} lists the parameter values obtained for each volunteer from this process. [Figure 7](#F7){ref-type="fig"}, *top*, shows the extent to which the average output of the model describes the mean data. For the hypercapnia protocol, the mean sensitivity obtained was 0.76 Torr per Torr change in P[et]{.smallcaps}~CO~2~~; for the hypocapnia protocol, the mean sensitivity was 0.40 Torr per Torr change in P[et]{.smallcaps}~CO~2~~. The sensitivities from these two protocols differed significantly (*P* \< 0.001, ANOVA). In the absence of further information from the literature concerning the degree to which the pulmonary vascular response to CO~2~ is curvilinear, we have adopted the assumption of linearity and used these data to give the coefficient δ(ΔPmax)/δP[co]{.smallcaps}~2~ in *[Eq. 14](#FD14){ref-type="disp-formula"}* a mean value of 0.58 Torr per Torr. For both protocols, the time constants for the response were similar (hypercapnia protocol = 4.9 min; hypocapnia protocol = 4.2 min).

![Example for a single volunteer (*number 1256*) of the fit of the model for the response of ΔPmax in 2 protocols. *Top*: hypercapnia protocol. *Bottom*: hypocapnia protocol. Solid lines = model response; symbols = experimental data points.](zdg0051090370006){#F6}

###### 

Model parameters for responses of ΔP~max~ and cardiac variables to hypercapnia and hypocapnia

                           ΔP~max~        HR            SV            Q̇                                                                                                                     
  ------------------------ -------------- ------------- ------------- -------------- ------------- ------------- -------------- ------------- ------------- --------------- --------------- --------------
  *Hypercapnia protocol*                                                                                                                                                                    
  *1229*                   22.46          0.90          4.27          ---            ---           ---           ---            ---           ---           ---             ---             ---
  *1096*                   26.28          0.64          2.63          49.89          1.12          2.04          98.52          1.00          0.01          4,895           172.5           1.66
  *1236*                   16.54          0.66          7.90          52.37          1.26          4.02          76.67          3.10          20.07         4,015           240.1           8.71
  *1238*                   14.96          0.39          4.99          40.92          0.59          7.56          64.31          1.78          7.82          2,624           119.3           7.77
  *1156*                   19.24          0.76          6.29          88.35          −0.75         1.66          60.28          0.59          0.94          5,304           7.240           0.02
  *1142*                   23.05          0.33          2.35          72.88          1.01          4.59          45.94          0.85          5.94          3,340           116.1           5.36
  *1091*                   23.06          0.72          2.74          51.85          1.22          5.21          123.74         1.46          3.85          6,402           240.5           4.63
  *1252*                   19.92          0.54          3.05          62.70          1.64          4.79          ---            ---           ---           3,991           164.9           8.12
  *1198*                   18.83          0.80          6.98          55.30          0.57          0.55          63.81          0.69          1.01          3,534           76.12           0.69
  *1250*                   20.04          0.92          6.75          59.05          1.60          5.89          80.00          0.63          2.34          4,725           168.1           4.36
  *1256*                   21.55          1.53          7.22          46.13          0.72          2.76          74.17          2.67          11.12         3,418           177.7           6.78
  *1209*                   20.77          0.90          3.08          59.36          0.63          3.17          89.33          1.57          6.95          5,303           152.6           4.92
  Means ± SE               20.56 ± 0.88   0.76 ± 0.09   4.85 ± 0.60   58.07 ± 3.98   0.87 ± 0.20   3.84 ± 0.62   77.68 ± 6.99   1.43 ± 0.28   6.01 ± 1.92   4,323 ± 333.4   148.6 ± 20.46   4.82 ± 0.90
  *Hypocapnia protocol*                                                                                                                                                                     
  *1229*                   25.50          0.42          5.66          55.25          −0.22         0.02          120.21         2.09          11.70         ---             ---             ---
  *1096*                   27.41          0.35          3.34          54.42          1.14          16.73         109.67         1.41          12.44         5,964           186.5           14.28
  *1236*                   15.82          0.22          4.46          ---            ---           ---           ---            ---           ---           ---             ---             ---
  *1238*                   16.33          0.20          1.41          ---            ---           ---           80.94          0.32          16.03         5,122           105.7           25.24
  *1156*                   25.74          0.66          5.36          89.00          0.73          2.13          62.19          0.51          7.84          5,515           81.01           4.03
  *1142*                   20.62          0.40          3.43          79.91          0.93          10.59         51.01          1.02          15.33         4,070           119.5           13.04
  *1091*                   25.84          0.47          5.98          52.64          0.68          12.59         112.19         0.66          5.83          5,902           103.2           9.39
  *1252*                   21.44          0.31          2.72          71.59          0.97          16.24         66.52          0.69          1.97          4,710           85.58           5.27
  *1198*                   19.02          0.39          4.12          47.89          −0.41         0.01          79.22          0.51          0.01          3,792           −6.65           0.01
  *1250*                   19.24          0.37          4.28          80.52          1.85          9.81          82.58          0.78          6.30          6,632           199.1           8.47
  *1256*                   20.50          0.57          6.54          47.57          0.34          13.79         ---            ---           ---           4,185           83.62           19.87
  *1209*                   22.05          0.41          2.72          65.37          1.35          15.06         93.78          0.84          3.55          6,111           152.2           8.34
  Means ± SE               21.63 ± 1.10   0.40 ± 0.04   4.17 ± 0.44   64.42 ± 4.76   0.74 ± 0.22   9.70 ± 2.09   85.83 ± 7.25   0.88 ± 0.16   8.10 ± 1.76   5,200 ± 308.9   111.0 ± 18.67   10.79 ± 2.39

*M*, value of variable under conditions of steady eucapnia; *G*, sensitivity of response to alterations in end-tidal P[co]{.smallcaps}~2~; τ, time constant for response; ΔPmax, maximum pressure difference across tricuspid valve; HR, heart rate; SV, stroke volume; Q̇, cardiac output. Parameter values for individual fits have been excluded for cases in which the models could not fit the data meaningfully.

![Average of the model outputs for ΔPmax, heart rate, stroke volume, and cardiac output compared with mean data. *Left*: hypercapnia protocol. *Right*: hypocapnia protocol. Solid lines = model response; symbols = experimental data points.](zdg0051090370007){#F7}

### Model parameters: cardiac variables.

[Table 1](#T1){ref-type="table"} displays the parameter estimates for each volunteer for the fit of the models to the data for Q̇, SV, and HR. Parameter values for individual fits have been excluded from [Table 1](#T1){ref-type="table"} when models could not fit the data meaningfully. [Figure 7](#F7){ref-type="fig"}, *bottom*, shows the extent to which the average outputs of these models describe the mean observations. Notable differences were observed between the time courses of the cardiac variables in hypercapnia and hypocapnia. During the hypercapnia protocol, HR changed rapidly with a time constant of 3.8 min, whereas, during the hypocapnia protocol, HR changed more slowly with a time constant of 9.7 min (*P* \< 0003, ANOVA). During the hypercapnia protocol, SV changed with a time constant of 6.0 min; during the hypocapnia protocol, it changed with a time constant of 8.1 min (*P* \< 0.04, ANOVA). During the hypercapnia protocol, Q̇ changed with a time constant of 4.8 min, whereas, during the hypocapnia protocol, Q̇ changed with a time constant of 10.8 min.

The sensitivities of Q̇, SV, and HR to changes in P[et]{.smallcaps}~CO~2~~ were similar in both the hypercapnia and hypocapnia protocols. These data were used to give the coefficient δQ̇/δP[co]{.smallcaps}~2~ in *[Eq. 14](#FD14){ref-type="disp-formula"}* a mean value of 0.130 l·min^−1^·Torr^−1^.

### Model parameters: order in which the measurements of ΔPmax and Q̇ were made.

To assess whether the measurements of ΔPmax and Q̇ were affected by the order in which they were made, we compared *M* (baseline) and *G* (sensitivity) for both ΔPmax and Q̇ and for both the hypercapnia and hypocapnia protocols, between the six volunteers for whom ΔPmax was measured first and the six volunteers for whom Q̇ was measured first. No significant differences were found for any of the eight comparisons. These results suggest that a wait of 4 h between a first and second exposure to 20 min of either hypercapnia or hypocapnia was sufficient to prevent the first exposure from influencing the results of the second exposure.

### Sensitivity of efficiency to changes in δ(ΔPmax)/δP[co]{.smallcaps}~2~ and δQ̇/δP[co]{.smallcaps}~2~.

*[Equations 14](#FD4){ref-type="disp-formula"}* and *17* can be combined to estimate the extent to which the calculated value of *E* is sensitive to variability between individuals in the measured values of δ(ΔPmax)/δP[co]{.smallcaps}~2~ and δQ̇/δP[co]{.smallcaps}~2~, respectively, tabulated as *G* for ΔPmax and *G* for Q̇ in [Table 1](#T1){ref-type="table"}. In the midrange of v̇/q̇ close to a value of 1, where *E* is 50% and the gain equals −1, we find that a 10% variation up or down in δ(ΔPmax)/δP[co]{.smallcaps}~2~ results in either a 2.7% increase or 3.1% decrease, respectively, in *E*. Correspondingly, we find a 10% variation up or down in δQ̇/δP[co]{.smallcaps}~2~ results in either a 0.4% decrease or 0.4% increase, respectively, in *E*. These relatively small changes in *E* suggest that the values of *E* shown in [Fig. 1](#F1){ref-type="fig"} are fairly insensitive to changes in the measured coefficients in *Eq. 14.*

### Correlation between δ(ΔPmax)/δP[co]{.smallcaps}~2~ and δQ̇/δP[co]{.smallcaps}~2~ for all volunteers.

It is of physiological interest to determine the extent to which sensitivities of ΔPmax and Q̇ to hypercapnia and hypocapnia are related to each other; does one high sensitivity within an individual imply that the second sensitivity will be high? The results suggest no significant correlation: *r* = 0.12 and *r* = −0.21 for hypercapnia and hypocapnia, respectively.

DISCUSSION
==========

The major finding of this study is that the efficiency of regulation of local v̇/q̇ by the pulmonary responses to P[co]{.smallcaps}~2~ and P[o]{.smallcaps}~2~ is ∼60% over the range of the v̇/q̇ values encountered in the healthy lung. The effects of O~2~ are dominant at values of v̇/q̇ below ∼0.65 and the effects of CO~2~ are dominant at values of v̇/q̇ above 0.65. Apart from providing coefficients for the CO~2~ component of the analysis, the experimental study also demonstrated that the dynamics of the pulmonary vascular response to CO~2~ were broadly comparable with those previously reported for O~2~.

Limitations of Theoretical Component of Study
---------------------------------------------

An assumption of the theory is that only q̇, and not v̇, is affected by the local composition of alveolar gas (*[Eq. 3](#FD3){ref-type="disp-formula"}*). However, there is evidence in the literature that airway gas composition can alter the distribution of v̇. Thus, for example, the presence of 5% carbon dioxide in the airways of anesthetized dogs during late inspiration reduces ventilation-perfusion heterogeneity, probably by a dilatory effect on airway smooth muscle in the conducting airways ([@B6]). In rat lungs ventilated with liquid, a direct measure of airway compliance during hypercapnia suggested bronchial and/or parenchymal relaxation ([@B8]). Correspondingly, bronchodilation of both small and large airways has been demonstrated during hypoxia in anesthetized miniature pigs by computed tomography ([@B41]). Another pertinent line of evidence suggesting that regulation of v̇ may occur in response to changes in alveolar gas is the measurable temporal variance of v̇ seen in anesthetized sheep ([@B30]), which may reflect changes in ventilation induced by changes in q̇ ([@B31]). It remains unclear to what extent these airway mechanisms contribute to ventilation perfusion matching during normal daily activities. If they do play a significant role, then the loop gains and efficiencies resulting from the effects of CO~2~ and O~2~ on perfusion that we have calculated in [Fig. 2](#F2){ref-type="fig"} represent approximate lower bounds for the overall effects of CO~2~ and O~2~ on ventilation perfusion matching in the lung.

A second feature of our analysis is that we infer local effects of hypercapnia and hypoxia on the pulmonary vasculature from the global effects of hypercapnia and hypoxia within the lung (*[Eq. 4](#FD4){ref-type="disp-formula"}*). The evidence that both CO~2~ and O~2~ act locally as vasoactive agents within the lung comes from a number of different approaches. In their early work, Kato and Staub ([@B15]) used rapid freezing of feline lung segments from locally hypoxic lobes to demonstrate that the major site of hypoxic constriction was in small muscular pulmonary arteries of internal diameter ∼200 μm at the level of terminal respiratory bronchioles. Their results also suggested that the combination of local hypercapnia and hypoxia yielded more vigorous constriction than hypoxia alone. Micropuncture studies by Nagasaka et al. ([@B25]) in in situ but otherwise isolated cat lungs confirmed that most of the constriction in response to hypoxia was above the level of arteries of diameter 30--50 μm and ameliorated by hypocapnia. In another direct approach, Shirai et al. ([@B35]) in 1986 used an X-ray television system to visualize the changes in diameter of small feline pulmonary vessels in the range of diameter 100--600 μm in response to both hypoxia and hypercapnia. Vigorous responses to both stimuli were at their maximum in arteries of internal diameter 200--300 μm, consistent with the older observations of Kato and Staub. Significantly, vessels in a second lobe remained unchanged when alveolar gas changes were restricted to the first lobe.

Less direct approaches have been consistent with the above findings. Hakim et al. ([@B12]) used sudden arterial and venous occlusions in isolated lung lobes of dogs and demonstrated that hypoxia acts mainly on small distensible vessels rather than on larger relatively indistensible arteries. The evidence of direct action of alveolar and mixed venous blood gases on small pulmonary vessels is further supplemented by fractal temporal analysis, which suggests that one level of regulation of regional blood flow is within components of lung tissue representing ∼3% of the lung ([@B10]). Finally, studies in anesthetized dogs of how acetazolamide impairs matching of ventilation and perfusion suggested that normal vascular (and bronchial) responses to changes in alveolar P[co]{.smallcaps}~2~ are both localized and rapid (on a timescale of ∼1 min) because of the local availability of carbonic anhydrase to speed changes in P[co]{.smallcaps}~2~ into changes in pH ([@B37], [@B38]).

However, such evidence cannot exclude the possibility that global hypercapnia or hypoxia may also exert global effects on pulmonary vascular tone through either neural or endocrine pathways, although the latter would seem unlikely given the relatively modest variations in P[co]{.smallcaps}~2~ and P[o]{.smallcaps}~2~ with which we are concerned. The pulmonary vasculature is innervated by both adrenergic and cholinergic nerves ([@B7], [@B13]), where the net effect of stimulation of the sympathetic system appears to be vasoconstriction and that of the cholinergic system is vasodilation ([@B26], [@B28]). Little is known regarding the effects of CO~2~ on the autonomic regulation of the pulmonary vasculature, but neither sympathetic nor complete autonomic blockade appears to modify the pulmonary vascular response to hypoxia once the confounding effects of these interventions on Q̇ have been taken into account ([@B18], [@B19]). We cannot exclude some error in our estimates arising from neuroendocrine mechanisms. Our analysis regarding the efficiency of regulation of local v̇/q̇ by the pulmonary responses to P[a]{.smallcaps}~CO~2~~ and P[a]{.smallcaps}~O~2~~ should therefore be regarded as speculative, pending further studies.

A third assumption within our analysis is that the local region of the lung in which the disturbance of v̇/q̇ occurs is small. Under this condition, alterations in local v̇/q̇ do not themselves give rise to changes in either ΔPmax ([@B21]) or the overall composition of systemic arterial blood. A change in this latter variable would be expected to induce changes in both ventilation and the composition of systemic mixed venous (pulmonary arterial) blood. In practice, many disturbances, such as changes in posture, may generate more widespread variations in v̇/q̇.

A fourth assumption of our analysis is that the effects of CO~2~ and O~2~ on the pulmonary vasculature are additive in nature. This assumption is used to calculate the total closed-loop gain and regulatory efficiency when the effects of both CO~2~ and O~2~ on the pulmonary circulation are combined. If the two stimuli were synergistic in their effects, then this would lead us to underestimate the magnitude of the total closed-loop gain. However, animal studies suggest that any such synergy is relatively small ([@B4], [@B34]).

Limitations of Experimental Component of Study
----------------------------------------------

The experimental component of this study examined the effect of variations in P[a]{.smallcaps}~CO~2~~ on an echocardiographic index of the in-flow pressure to the pulmonary circulation. A complication of any such study is that changes in the in-flow pressure will be affected by changes in Q̇ induced by CO~2~ as well as by the direct effect of CO~2~ on the pulmonary vascular smooth muscle. For O~2~, the contribution of changes in Q̇ to the overall change in ΔPmax appears to be small (∼5%) in the normal lung ([@B3]). For CO~2~, the data in this study suggest that the contribution of changes in Q̇ to the overall change in ΔPmax is ∼10--15%. However, it is important to appreciate that the theoretical component of this study does not rely on the small size of the overall contribution of Q̇ to changes in ΔPmax. Our theory treats ΔPmax as a function of both Q̇ and alveolar gas tension.

Second, it is also possible that inflow pressure is affected independently by different levels of ventilation. Ventilation in the hypercapnia protocol was higher than in the hypocapnia protocol, and this might be related to the differences in the values of *G* computed for ΔPmax for these two stimuli. An indication that any such effect may be minimal comes from the data for the eucapnic 5-min period at the beginning of each of the protocols when the level of ventilations differed. During this period, the voluntary hyperventilation reported above for the hypocapnia protocol was 10.3 l/min greater than the spontaneous ventilation in the hypercapnia protocol, whereas ΔPmax was only 1.07 Torr greater in the former protocol ([Table 1](#T1){ref-type="table"}). Given that Q̇ in the hypocapnia protocol during this period was 877 ml/min greater than in hypercapnia protocol ([Table 1](#T1){ref-type="table"}), these observations are consistent with hyperventilation having a small effect on ΔPmax through an increase in Q̇, as observed elsewhere ([@B3]). By taking a mean value of *G* from the two protocols, we have attempted to minimize any effect of ventilation on the measurements of ΔPmax.

A third limitation to the experiment is the possibility that a rise in mixed venous P[co]{.smallcaps}~2~ during hypercapnia and a fall in mixed venous P[co]{.smallcaps}~2~ during hypocapnia might independently affect in-flow pressure to the lungs. If this were to occur, then the assumption underlying *[Eq. 5](#FD5){ref-type="disp-formula"}*, namely, that for the lung as a whole ΔPmax may be regarded as a function of both Q̇ and P[a]{.smallcaps}~CO~2~~, would no longer be valid. We know of no data in humans that address this question, but a study in sheep using extracorporeal circulation separately to elevate mixed venous P[co]{.smallcaps}~2~ and lower mixed venous P[o]{.smallcaps}~2~ while holding alveolar gas composition constant found little change in pulmonary artery pressure ([@B33]). The small changes seen were compatible with being attributable to small changes in Q̇ alone.

Physiological Significance of Calculated Efficiency
---------------------------------------------------

The overall efficiency for regulation of v̇/q̇ by the combined effects of CO~2~ and O~2~ on the pulmonary vasculature has been estimated in this study at ∼60%. On the one hand, an efficiency of 60%, which corresponds to a closed-loop gain of −1.5, may be considered to provide a reasonable degree of correction in response to a disturbance. On the other hand, other physiological control systems can have far higher closed-loop gains. For example, the steady-state closed-loop gain for the ventilatory system regulating arterial P[co]{.smallcaps}~2~ is perhaps approximately −20 for an individual who is breathing air under resting conditions. The efficiency associated with this is ∼95%. One possible reason for the limited magnitude of the closed-loop gain for the control of v̇/q̇ is that higher gains could result in an excessive degree of pulmonary hypertension if conditions of global hypercapnia/hypoxia were to occur.

Our calculations are for disturbances of relatively short duration, such as might be generated, for example, by changes in posture or by the known cyclical changes in functional residual capacity with a period between 8 and 28 min ([@B14]). Longer disturbances are likely to give rise to greater efficiencies because the sensitivities of pulmonary vasoconstriction to both hypercapnia ([@B2]) and hypoxia ([@B23], [@B39]) increase over longer periods. Our calculations apply to healthy lungs under resting conditions, perfused with blood of a standard mixed venous composition and ventilated with air at sea level. Further investigations would be required to assess the roles of hypercapnic and hypoxic pulmonary vasoconstriction in other settings.

There are very few other studies that have tried to assess the functional significance of pulmonary vascular reactivity to CO~2~ and O~2~ for v̇/q̇ matching within the normal lung. However, one such study is that of Grant et al. ([@B11]), who wedged fine bronchial catheters in subsegmental bronchi of anesthetized coatimundi, measured changes in regional blood flow in response to changes in alveolar gas composition, and applied control theory to these measurements to predict the strength of the feedback control of perfusion provided by the vasomotor responses. In this preparation, it was found that changes in P[a]{.smallcaps}~O~2~~ around physiological values had larger effects than changes in P[a]{.smallcaps}~CO~2~~ and that the feedback responses were typically capable of reducing perturbations in regional blood flow to ∼50% of their initial value in the absence of the feedback. The latter result is very similar to the findings of the present study.

Although not within the setting of the normal lung, Brimioulle et al. ([@B5]) used stimulus response data from experiments on dogs to estimate the contribution of hypoxic pulmonary vasoconstriction to the matching of perfusion to ventilation in lung injury. Naeije and Brimioulle ([@B24]) have interpreted these calculations as suggesting that, in both chronic obstructive pulmonary disease and acute respiratory distress syndrome, hypoxic pulmonary vasoconstriction may typically increase arterial P[o]{.smallcaps}~2~ by up to 20 Torr.

Comparison of Experimental Findings With Other Results From the Literature
--------------------------------------------------------------------------

The literature contains relatively few data on the effects of CO~2~ on the pulmonary circulation compared with the immense number of publications on the effects of hypoxia. Indeed, analyses of the control of the pulmonary circulation by alveolar and mixed venous gases have typically considered only the effects of hypoxia ([@B5], [@B21]). The findings of the present study confirm those of earlier studies that showed a marked vasoconstrictor effect of hypercapnia on the pulmonary circulation ([@B2], [@B4], [@B16], [@B17], [@B34]). Few studies have examined the effects of hypocapnia on the pulmonary circulation. In relation to this, one influential view has been that "because of the low initial tone, attempts to vasodilate the normal pulmonary circulation are destined to be fruitless" ([@B9]). However, the present study confirms earlier findings in both sheep ([@B34]) and humans ([@B2]) that hypocapnia induces significant pulmonary vasodilatation within the lung.

A novel finding from this study is that the initial human pulmonary vascular response to CO~2~ has a time constant of the order of 4--5 min, which is of the same order of magnitude as the time constant of ∼2--3 min that has been reported for the initial human pulmonary vascular response to hypoxia ([@B23], [@B39]). This finding suggests that fairly rapid adjustments can be generated by CO~2~ as well as by O~2~ in response to activities such as changes in posture.
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